

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED

和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
ABSTRACTS OF PHASE I DATA OF NEXT-GENERATION ANTI-CTLA-4
ANTIBODY HBM4003 TO BE PRESENTED AT ESMO CONGRESS 2021

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the clinical data abstracts from the Company’s Australian Phase I study of HBM4003 (anti-CTLA-4 antibody) in patients with advanced solid tumor (the “**Study**”) will be presented by way of an e-poster at the 2021 European Society for Medical Oncology (ESMO) Congress, which is expected to be held from 16 to 21 September 2021.

The Study is an open-label, dose-escalating monotherapy study in treatment of advanced solid tumors. The preliminary clinical data demonstrates encouraging anti-tumor efficacy of HBM4003, with the good safety profile. HBM4003’s novel and differentiated mechanism of action has the potential to improve efficacy of treatment while significantly reducing the toxicity of the drug. The data obtained from the Study has further validated pre-clinical findings of HBM4003’s unique PK/PD profile, novel mechanism of action and low immunogenicity. The Company has proceeded with multiple global Phase Ib/IIa trials in solid tumors in light of the encouraging clinical efficacy and safety profile.

About HBM4003

HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice[®]. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

Cautionary Statement: We cannot guarantee that we will be able to develop, or ultimately market, HBM4003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 26 July 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.